Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213055 · ClinicalTrials.gov registry record · Phase 2
Pediatric Head Lice Study Product Comparison
A Phase 2 study of Head Lice, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT02213055: Completed Phase 2 study of Head Lice, sponsored by Hackensack Meridian Health.
NCT02213055 is a Phase 2 study of Head Lice that has completed, run by Hackensack Meridian Health. The registered enrollment target is 97 participants, roughly in line with the 97-participant average among 5 other Head Lice trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02213055, a Phase 2 study of Head Lice, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
* To evaluate the efficacy of LiceMD for the treatment of head lice in a pediatric population. * To evaluate the safety of LiceMD in a pediatric population.
Primary Outcome
A determination of head lice effectiveness, measured by number of subjects free of live lice and by number of subjects free of viable eggs, was calculated using two week post-treatment data as the primary study outcome. Measurements were calculated at Day 1 (day after first treatment) and Day 14. At diagnosis, 55 subjects had viable eggs with three subjects meeting enrollment criteria for three or more live lice.
Conditions Studied
Interventions
- DRUG LICEMD
- DRUG Standard Head lice product
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT02213055 record still lists
NCT02213055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, roughly in line with the 97-participant average among 5 other Head Lice trials with a reported enrollment target.
The record links to 1 condition, with Head Lice appearing as the primary indexed condition, and to 2 interventions - of which LICEMD is the first listed.
NCT02213055 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02213055 about?
NCT02213055 is a clinical study titled "Pediatric Head Lice Study Product Comparison". * To evaluate the efficacy of LiceMD for the treatment of head lice in a pediatric population. * To evaluate the safety of LiceMD in a pediatric population.
What is the current status of trial NCT02213055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2009-05. Estimated completion is 2014-08.
What conditions does trial NCT02213055 study?
This clinical trial studies the following conditions: Head Lice.
What interventions are being tested in trial NCT02213055?
The interventions under investigation include: LICEMD (DRUG), Standard Head lice product (DRUG).
Who is sponsoring clinical trial NCT02213055?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02213055 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Lice
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
COMPLETED · Phase 2
-
A Pilot Dose Ranging Study of Spinosad Creme Rinse
COMPLETED · Phase 2
-
Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo
RECRUITING · NA
-
A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.
COMPLETED · NA
-
Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia